Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran Inc (BIXT) is a clinical-stage biotechnology company pioneering novel therapies for hypoxia-related conditions and antiviral applications. This page serves as the definitive source for official company announcements, research breakthroughs, and regulatory developments.
Investors and industry professionals will find timely updates on Bioxytran's drug candidates including BXT-25 for stroke-related ischemia and Prolectin-M antiviral research. Our curated news collection features press releases, clinical trial milestones, partnership announcements, and financial disclosures.
All content is verified through primary sources, with emphasis on material developments in the company's AI-driven drug discovery platform and NMR-based molecular analysis. Bookmark this page for streamlined access to critical updates about therapeutic advancements in neurology, wound healing, and viral infection management.
BIOXYTRAN, INC. (BIXT) announced successful animal testing results for its Acellular Oxygen Carrier BXT-25, designed to treat COVID-19 and other viral diseases. The treatment showed non-toxicity and full recovery in Swiss Albino mice, even after a significant blood loss. BXT-25 is significantly smaller than a blood cell, allowing it to reach hypoxic areas of the body, potentially revolutionizing treatment for conditions like strokes and neurodegenerative diseases. The company plans to conduct further toxicity studies and aims to submit an Investigational New Drug Application to the FDA for clinical trials on stroke patients. Initial non-clinical studies indicated no toxicity and effective oxygen delivery, bolstering the drug's therapeutic potential.
BIOXYTRAN, INC. (OTCQB: BIXT) is set to present new findings on its Long COVID research at the Emerging Growth Conference on April 5, 2023, from 10:50am to 11:20am EST. CCO Michael Sheikh will discuss a recent peer-reviewed journal article and engage with attendees. Investors are encouraged to preregister for the event to receive updates and have the opportunity to submit questions. Bioxytran is developing innovative antiviral treatments, focusing on unmet medical needs in virology. The conference serves as a platform for public companies to showcase advancements, attracting a broad audience of investors.
Bioxytran, Inc. (BIXT) announced promising results from a Phase 2 clinical trial for its Galectin antagonist, demonstrating a 100% viral load elimination in 34 patients with mild-to-moderate COVID-19 by day 7, compared to just 6% in the placebo group (p=.001). Most symptoms resolved within the same period. The trial showed an 82% responder rate by day 3 (p=.001) with no serious adverse events. These results support further studies, possibly a Phase 3 trial, highlighting the drug's potential in both treatment and prophylaxis against viral infections. Bioxytran aims to explore applications beyond COVID-19, tapping into Glycovirology.
Bioxytran, Inc. (OTCQB: BIXT) has reported promising in vitro results for its leading drug candidate ProLectin-M (PL-M), demonstrating a significant reduction in viral load for influenza (H1N1) and Respiratory Syncytial Virus (RSV). Conducted at the Foundation for Neglected Disease Research in India, these tests mirror previous SARS-CoV-2 results that led to successful trials. The company plans to file an IND to advance to phase 2 human clinical trials. With this data, Bioxytran aims to expand treatment options for viral diseases amid the rise of concurrent infections known as the 'tripledemic.'
BIOXYTRAN, INC. (OTCQB: BIXT) has announced that a peer-reviewed article published in Nature Reviews Drug Discovery supports its drug development for fibrosis and antiviral treatments. The article, titled “Targeting galectin-driven regulatory circuits in cancer and fibrosis”, highlights the significance of galectins in diseases like Idiopathic Pulmonary Fibrosis (IPF) and Long COVID. ProLectin-M, an oral drug, showed a 100% responder rate in clinical trials for COVID-19, while ProLectin-I, an intravenous drug, aims to tackle Long COVID and IPF. The ongoing studies and supportive literature enhance the prospects for regulatory approval.
Bioxytran, Inc. (OTCQB: BIXT) announced that CCO Michael Sheikh will participate in a ClearThink IR Virtual Live event on February 15, 2023, at 12 PM ET. The event, hosted via the Paltalk platform, aims to engage potential investors with Q&A discussions about the company’s innovative therapies targeting viral diseases and other medical needs. Bioxytran is focused on developing Prolectin-M, a new class of antiviral drug, along with treatments for pulmonary fibrosis and stroke. Registration for the event is available on their website.
BIOXYTRAN, INC. (OTCQB: BIXT) received Investigational New Drug (IND) authorization from India’s CDSCO to evaluate ProLectin-I for treating Long COVID and Idiopathic Pulmonary Fibrosis (IPF). This IND complements a previous authorization for ProLectin-M. ProLectin-I could address a significant health challenge, with Long COVID affecting 65-100 million globally and an estimated economic cost of $3.7 trillion in the U.S. alone. IPF impacts about 3 million people worldwide. The drug targets viral persistence associated with Long COVID and lung fibrosis.
Bioxytran, Inc. (OTCQB: BIXT) announced that its CMO, Michael Sheikh, will discuss the company's participation in the Emerging Growth Conference on January 25, 2023, at 10:50 am EST. The conference will feature presentations by public companies across various growth sectors, focusing on innovative products and long-term growth potential. Investors are encouraged to preregister for attendance, and an archived webcast will be available post-event. Bioxytran is a clinical-stage biotechnology firm developing therapies for COVID-19 and other diseases, with its lead candidate being Prolectin-M, aimed at treating significant unmet medical needs.
BIOXYTRAN, INC. (OTCQB: BIXT) announced positive outcomes from its Phase 2 clinical trial for ProLectin-M, a treatment for COVID-19. The trial achieved a 100% response rate by day 7 in 34 patients, significantly outperforming the placebo (6%). Additionally, the company received an IND letter from India's CDSCO to optimize dosage for a planned 408 patient Phase III trial. An Indian subsidiary has been established to commercialize ProLectin-M upon approval, utilizing an FDA-approved manufacturing plant aimed at the 1.4 billion population in India.
BIOXYTRAN, INC. (OTCQB: BIXT) announces the establishment of its Indian subsidiary, Pharmalectin India Private Limited, aimed at launching ProLectin-M upon receiving CDSCO approval. The FDA-approved facility is positioned to cater to India's vast market of 1.4 billion. Currently, the company has not secured a distributor for its products. ProLectin-M, Bioxytran's leading drug candidate, targets viral diseases and shows promise in treating unmet medical needs. Further details can be found on their website.
